Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Response to Senate HELP Committee RFI on Diagnostics Regulation
-
ACMG Comments on FDA Proposed Rule for Regulation of LDTs
-
Stakeholder Letter Asking Congress Renew Efforts on CLIA Reform and Urge FDA to Halt LDT Rulemaking
-
Letter to FDA Requesting Extension of Comment Period for Proposed Rule on Regulation of LDTs
-
ACMG Request to FDA to Extend Comment Period for Proposed Rule on Regulation of LDTs
-
ACMG Comments on CY 2024 Physician Fee Schedule Proposed Rule
-
Sign-on Letter Regarding the Novitas & FCSO Proposed LCD on Genetic Testing for Oncology
-
Sign-on Letter Asking CMS to Add Medical Nutrition an Essential Health Benefit
-
Sign-on Letter Concerning the Improving Care and Access to Nurses Act
-
Sign-on Letter Opposing Cigna Policy on Use of Modifier -25